Oliver John Watson

Oliver John Watson

Auto-generated profile, based on publicly available information

Oliver John Watson

Imperial College London

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
OWOliver J Watson
Oliver J Watson
GBGregory Barnsley
Gregory Barnsley
JTJaspreet Toor
Jaspreet Toor
AHAlexandra B Hogan
Alexandra B Hogan
PWPeter Winskill
Peter Winskill
AGAzra C Ghani
Azra C Ghani
The first COVID-19 vaccine outside a clinical trial setting was administered on Dec 8, 2020. To ensure global vaccine equity, vaccine targets were set by the COVID-19 Vaccines Global Access (COVAX) Facility and WHO. However, due to vaccine shortfalls, these targets were not achieved by the end of 2021. We aimed to quantify the global impact of the first year of COVID-19 vaccination programmes. A mathematical model of COVID-19 transmission and vaccination was separately fit to reported COVID-19 mortality and all-cause excess mortality in 185 countries and territories. The impact of COVID-19 vaccination programmes was determined by estimating the additional lives lost if no vaccines had been distributed. We also estimated the additional deaths that would have been averted had the vaccination coverage targets of 20% set by COVAX and 40% set by WHO been achieved by the end of 2021. Based on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million (95% credible interval [Crl] 13·7–15·9) deaths from COVID-19 in 185 countries and territories between Dec 8, 2020, and Dec 8, 2021. This estimate rose to 19·8 million (95% Crl 19·1–20·4) deaths from COVID-19 averted when we used excess deaths as an estimate of the true extent of the pandemic, representing a global reduction of 63% in total deaths (19·8 million of 31·4 million) during the first year of COVID-19 vaccination. In COVAX Advance Market Commitment countries, we estimated that 41% of excess mortality (7·4 million [95% Crl 6·8–7·7] of 17·9 million deaths) was averted. In low-income countries, we estimated that an additional 45% (95% CrI 42–49) of deaths could have been averted had the 20% vaccination coverage target set by COVAX been met by each country, and that an additional 111% (105–118) of deaths could have been averted had the 40% target set by WHO been met by each country by the end of 2021. COVID-19 vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact in these settings, reinforcing the need for global vaccine equity and coverage. Schmidt Science Fellowship in partnership with the Rhodes Trust; WHO; UK Medical Research Council; Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation; National Institute for Health Research; and Community Jameel.

24 July 2020 in Science
Verified
Journal Article
Open access
PDF file
PWPatrick G. T. Walker
Patrick G. T. Walker
CWCharles Whittaker
Charles Whittaker
OWOliver J. Watson
Oliver J. Watson
MBMarc Baguelin
Marc Baguelin
PWPeter Winskill
Peter Winskill
AGAzra C. Ghani
Azra C. Ghani
Global prospects for COVID-19 control: Lower-income countries have recognized the potential impact of coronavirus disease 2019 (COVID-19) from observing ongoing epidemics. Many have intervened quickly and early with measures to slow viral transmission, which may partly explain the low rates observed so far in these countries. Walker et al. calibrated a global model with country-specific data (see the Perspective by Metcalf et al. ). Despite the potentially protective effects of younger demographics, the closer intergenerational contact, limitations on health care facilities, and frequency of comorbidities in lower-income countries require sustained nonpharmaceutical interventions (NPIs) to avoid overwhelming health care capacity. As a result of strict NPIs, the protective effects of immunity will be reduced, and it will be important to improve testing capacity. Ensuring equitable provision of oxygen and—when they are ready—pharmaceutical interventions should be a global priority. Science , this issue p. 413 ; see also p. 368

17 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PNPierre Nouvellet
Pierre Nouvellet
SBSangeeta Bhatia
Sangeeta Bhatia
ACAnne Cori
Anne Cori
KAKylie E. C. Ainslie
Kylie E. C. Ainslie
MBMarc Baguelin
Marc Baguelin
CDChristl A Donnelly
Christl A Donnelly
In response to the COVID-19 pandemic, countries have sought to control SARS-CoV-2 transmission by restricting population movement through social distancing interventions, thus reducing the number of contacts. Mobility data represent an important proxy measure of social distancing, and here, we characterise the relationship between transmission and mobility for 52 countries around the world. Transmission significantly decreased with the initial reduction in mobility in 73% of the countries analysed, but we found evidence of decoupling of transmission and mobility following the relaxation of strict control measures for 80% of countries. For the majority of countries, mobility explained a substantial proportion of the variation in transmissibility (median adjusted R-squared: 48%, interquartile range - IQR - across countries [27–77%]). Where a change in the relationship occurred, predictive ability decreased after the relaxation; from a median adjusted R-squared of 74% (IQR across countries [49–91%]) pre-relaxation, to a median adjusted R-squared of 30% (IQR across countries [12–48%]) post-relaxation. In countries with a clear relationship between mobility and transmission both before and after strict control measures were relaxed, mobility was associated with lower transmission rates after control measures were relaxed indicating that the beneficial effects of ongoing social distancing behaviours were substantial.

19 February 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MKMoritz U. G. Kraemer
Moritz U. G. Kraemer
JTJoseph L.-H. Tsui
Joseph L.-H. Tsui
SCSerina Y. Chang
Serina Y. Chang
SLSpyros Lytras
Spyros Lytras
MKMark P. Khurana
Mark P. Khurana
SBSamir Bhatt
Samir Bhatt

7 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ESEllie Sherrard-Smith
Ellie Sherrard-Smith
AHAlexandra Hogan
Alexandra Hogan
AHArran Hamlet
Arran Hamlet
OWOliver J. Watson
Oliver J. Watson
CWCharlie Whittaker
Charlie Whittaker
TCThomas S. Churcher
Thomas S. Churcher

3 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HUH. Juliette T. Unwin
H. Juliette T. Unwin
SMSwapnil Mishra
Swapnil Mishra
VBValerie C. Bradley
Valerie C. Bradley
AGAxel Gandy
Axel Gandy
TMThomas A. Mellan
Thomas A. Mellan
SFSeth Flaxman
Seth Flaxman
As of 1st June 2020, the US Centres for Disease Control and Prevention reported 104,232 confirmed or probable COVID-19-related deaths in the US. This was more than twice the number of deaths reported in the next most severely impacted country. We jointly model the US epidemic at the state-level, using publicly available death data within a Bayesian hierarchical semi-mechanistic framework. For each state, we estimate the number of individuals that have been infected, the number of individuals that are currently infectious and the time-varying reproduction number (the average number of secondary infections caused by an infected person). We use changes in mobility to capture the impact that non-pharmaceutical interventions and other behaviour changes have on the rate of transmission of SARS-CoV-2. We estimate that Rt was only below one in 23 states on 1st June. We also estimate that 3.7% [3.4%–4.0%] of the total population of the US had been infected, with wide variation between states, and approximately 0.01% of the population was infectious. We demonstrate good 3 week model forecasts of deaths with low error and good coverage of our credible intervals.